Financings Of The Fortnight: In The Aftermath Of Facebook IPO, Kythera Steps Up, TVAX And Cancer Genetics Back Off
This article was originally published in The Pink Sheet Daily
Executive Summary
Plus news on recent financing activity by TVM Capital, Royalty Pharma, Prosonix and Sangart.
You may also be interested in...
Lilly And Canadian VCs To Fund TVM Life Sciences VII To Develop Single-Asset Companies
Lilly and Canadian VCs back a new TVM Life Sciences fund that will invest in a network of single-asset companies in Quebec.
Prosonix Extends Series B Financing, Plans Generic Fluticasone Filing
Prosonix receives an extra $9 million for its Series B round as it changes business strategy from contract research to the development of generic respiratory products, based on a novel particle-engineering technology for inhaled powders.
Financings Of The Fortnight Sees New Biotech Funding All Over The Globe, And Without Much VC Participation
Plus news on recent financial activity by Merrimack, Promethera, ADC Therapeutics and Enterome Bioscience.